Carla Walraven

Dr. Carla Walraven


Research Focus & Metrics

Academic Career Length

16Years (2011-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
20 July 2011 in Journal of Antimicrobial Chemotherapy
Verified
Journal Article
Open access
PDF file
CWCarla Walraven
Carla Walraven
MNMichael S. North
Michael S. North
LMLisa Marr-Lyon
Lisa Marr-Lyon
PDPaulina Deming
Paulina Deming
GSGeorge Sakoulas
George Sakoulas
RMRenée-Claude Mercier
Renée-Claude Mercier
Therapeutic use of vancomycin is characterized by decreased susceptibilities and increasing reports of clinical failures. Few studies have examined the clinical outcomes of patients with methicillin-resistant Staphylococcus aureus (MRSA) bacteraemia treated with vancomycin. The primary objective was to compare clinical outcomes of patients with MRSA bacteraemia treated according to standard of care practices. Patients were included if: (i) admitted to University of New Mexico Hospital between 2002 and 2009; (ii) ≥18 years of age; (iii) had one blood culture positive for MRSA; and (iv) received vancomycin. Clinical outcomes were defined as cure, failure (relapse of infection 30 days after completion of therapy, death or change in therapy) or unevaluable. Patient demographics, source of bacteraemia, treatment regimen, and microbiological characteristics were determined. Two hundred patients with MRSA bacteraemia were included. Sixty-one patients were unevaluable, leaving 139 patients for the final analysis. Seventy-two (51.8%) patients were cured and 67 (48.2%) experienced vancomycin failure. Vancomycin MIC90 was 2 mg/L for both groups by Etest. Patients with endocarditis (P = 0.02) or pneumonia (P = 0.02) were more likely to fail therapy. Panton–Valentine leucocidin, loss of agr functionality and strain type were not predictors of outcomes in this study. High failure rates were observed in patients with MRSA bacteraemia treated with vancomycin, despite high vancomycin troughs and low rates of nephrotoxicity. Predictors of vancomycin failure included endocarditis and pneumonia. In these situations, vancomycin provides suboptimal therapy.

21 June 2022 in The Journal of Clinical Pharmacology
Verified
Journal Article
Closed access
GRGerardo P. Ramos‐Otero
Gerardo P. Ramos‐Otero
PSPreeyaporn Sarangarm
Preeyaporn Sarangarm
CWCarla Walraven
Carla Walraven


24 July 2015 in Antibiotics
Verified
Journal Article
Open access
PDF file
JRJennifer L. Ross
Jennifer L. Ross
SRShannon Rankin
Shannon Rankin
PMPatricia Marshik
Patricia Marshik
RMRenée-Claude Mercier
Renée-Claude Mercier
MBMeghan Brett
Meghan Brett
CWCarla Walraven
Carla Walraven
Infectious Diseases specialists have used high-dose daptomycin (≥6 mg/kg/day) in select patients with difficult to treat methicillin-resistant Staphylococcus aureus (MRSA) or vancomycin-resistant Enterococcus (VRE) infections to optimize outcomes. Antimicrobial stewardship programs enforce antimicrobial formulary restrictions; however, interventions specifically aimed at Infectious Disease specialists can be particularly challenging. The purpose of this study was to create a high-dose daptomycin algorithm for Infectious Disease specialists that are consistent with best-practices. Daptomycin prescribing habits pre- and post-daptomycin algorithm implementation were evaluated using a quasi-experimental study design. Patients were included if ≥18 years of age and received daptomycin for ≥48 h. Patients were excluded if daptomycin was initiated on an outpatient setting. During the 12-month pre-intervention phase, 112 patients were included, with 73 patients in the 12-month post-intervention phase. A statistically significant decrease in the mean daptomycin dose from 9.01 mg/kg to 7.51 mg/kg (p < 0.005) was observed, resulting in an annual drug cost-savings of over $75,000 without adversely affecting readmission rates due to infection. Creation of a daptomycin algorithm with consideration of pathogen, disease state, and prior treatment, is an effective means of influencing prescribing habits of Infectious Disease specialists.

26 June 2024 in Open Forum Infectious Diseases
Verified
Journal Article
Open access
PDF file
SASara F Azimi
Sara F Azimi
EGEsther Golnabi
Esther Golnabi
RMRyan P Mynatt
Ryan P Mynatt
DBDonna Burgess
Donna Burgess
ALAshley Logan
Ashley Logan
CWCarla Walraven
Carla Walraven
Background: Outpatient parenteral antimicrobial therapy (OPAT) regimens typically prioritize ease of antimicrobial administration, tolerability, safety, and accessibility over using the narrowest-spectrum antimicrobial. In light of this, OPAT providers often utilize different techniques to promote antimicrobial stewardship (AMS) in their OPAT programs. This study aims to characterize the AMS practices of OPAT programs across the United States that might meet The Joint Commission requirements for outpatient AMS metrics. Methods: This is a cross-sectional electronic survey of the Vizient AMS network. A total of 95 possible questions were designed to inquire about demographics, OPAT program structure, AMS initiatives, performance metrics, and resources. Results: Seventy-four survey responses were received, with 58 (78.4%) of the respondents indicating their institution offered OPAT services. Respondents reported having at least 1 AMS protocol and tracking at least 1 metric in 91% and 74% of OPAT programs, respectively. Only 40% of programs reported billing for OPAT-related services. Approximately 45% of respondents disagreed or strongly disagreed that their OPAT program had the resources needed to care for the population it serves. Respondents identified data analytics (69%), funding for expansion of services (67%), and pharmacists (62%) as resources of greatest need for their OPAT programs. Conclusions: This survey collectively describes the AMS practices currently employed by OPAT programs across the United States. The results provide specific examples of AMS initiatives, metrics, and resources that institutions may reference to advance the practices of their OPAT programs to meet The Joint Commission Outpatient Antimicrobial Stewardship standards.

28 October 2023 in European Journal of Clinical Pharmacology
Verified
Journal Article
Closed access
PDF file
DGDiari Gilliam
Diari Gilliam
DADominic Acosta
Dominic Acosta
MCMartha L. Carvour
Martha L. Carvour
CWCarla Walraven
Carla Walraven